



Publishing options: Couperin associated corresponding authors



1. Key definitions

Terminology	Definition
Submitting corresponding author	<p>Submitting corresponding author is the author who submits the article to Elsevier and stays in contact with Elsevier in the end-to-end journey</p> <p>This is the author who makes the publishing choice on behalf of the author group</p> <p>Every article has one corresponding author</p>
Acceptance Date	<p>This is the date the journal accepts the article for publication</p>
Elsevier OA Platform	<p>Elsevier OA Platform (EOAP) is a user-friendly interface where we present the institutional administrators with the open access articles eligible for the agreement.</p> <p>Administrators at the institution validate the eligibility of the author for an OA agreement</p>
Gold Open Access	<p>The final version of the published journal article is made freely available, immediately, to everyone. An author can publish Gold Open Access in an open access journal OR in a Hybrid journal which offers open access</p>

2. Eligibility criteria

Eligibility component	Description
Acceptance date	The acceptance date of the article should fall within the period of agreement for your institution
Author affiliation	The submitting corresponding author must be affiliated with a participating institution in the agreement.
Journal title	The article must be submitted to and accepted in a participating journal.
APC available	Institution has APCs for the year

3. Agreement Overview

Journal Bucket	Agreement
Core Hybrid/ Core Gold	The eligible submitting corresponding authors receive full APC coverage upon validation in EOAP. All institutions have a quota of 11138/11268/11410/11566 for 2024-2027
Cell Press/Lancet Hybrid & Gold	The eligible submitting corresponding authors receive 10% discount upon validation in EOAP

Publishing options at submission (Editorial Manager)

5

As part of the submission journey, once the author uploads the manuscript files, corresponding author provides the affiliation details

Edit Author Details [Close]

Mr. Bharath Aradhyula [Corresponding Author] [First Author] [You]

[Insert Special Characters](#)

Your Given/First Name*
Middle Name

Your Family/Last Name*
Academic Degree(s)

Your E-mail Address*
ORCID [Fetch/Register](#)

[What is ORCID?](#)

Institution*
Nantes University
Nantes, FR

Country or Region
Nantes Universite
Nantes, FR

Contributor Roles*

- Nantes Université
Nantes, FR
- University of Nantes
Nantes, FR
- Centre Hospitalier Universitaire de Nantes
Nantes, FR
- University Hospital Centre Nantes

Current Author List

Mr. Bharath Ara

[Add Another Author](#)

[Back](#) [Save & Submit Later](#) [Build PDF for Approval](#)

Corresponding author also provides the research funder details if applicable. Clicking on 'Build PDF for Approval' will take them to the next page

+ Add Another Author

↓ Next

Funding Information

Please choose a funding source from the list that displays as you start to enter the funder's name. If you are unable to make a selection from the list you can continue to enter the entire funder's name. Then enter the award number and select the award recipient.

If providing details for two or more organizations, please list the organization(s) that provided the most funding first, as this will help us determine the publishing options for your article.

Required ✓

Current Funding Sources List

There are currently no Funding Sources in this list.

+ Add a Funding Source

Funding information is required

Add New Funding Source [Close]

Insert Special Characters

Find a Funder: Milliman

Award Number: GT123

Grant Recipient: Arnold Stanly

← Back Save & Submit Later Build PDF for Approval →

The author only needs to provide the affiliation and funder details once as we will copy this into the post acceptance journey

System presents information about the publishing options and informs that the choice the author makes at submissions is an indication



International Journal of Pharmaceutics

[Home](#)

[Main Menu](#)

[Submit a Manuscript](#)

[About](#)

[Help](#)

Elsevier Publishing Options

Please indicate your Publishing Options

This is a hybrid journal. The journal publishes both subscription and OA articles. We will present your personalized Publishing Options based on the Institution and Funding details you have given us. Please note that at this stage in your submission, you are only indicating your preference. We will ask you to make a final choice after the journal has accepted your manuscript.

[Publishing Options](#)

[Cancel](#)

[Proceed](#)



Publishing options in a Hybrid journal

i Based on the information you have provided, these are your publishing options.
If the journal accepts your article, you can change your mind about these options.
Note: editors and reviewers can only see your selection after acceptance.
This is a Transformative Journal 

iqwhnoief 

Gold Open Access

Publish as an Open Access article

Make my final published article available to everyone upon acceptance.

I am an author affiliated with the **Nantes University**. As there is an [agreement in place between the French higher education and research institutions consortium \(Couperin\) and Elsevier](#) to cover the APC (Article Publishing Charge) for publishing Open Access, I do not have to pay an APC if **all** of the following criteria are met:

- My institution has APCs available by the time the journal accepts the article
- My institution approves using the agreement funds to pay the APC

To pay on acceptance	
 Only applicable if article accepted	
 APC	Price EUR 3,120.00
	Institutional Agreement Discount - 3,120.00
	<hr/>
	To pay (on validation) 0.00

Subscription

Publish as a subscription article

I will publish my article subscription, making my final published article immediately available to journal subscribers, and to other groups as part of [Elsevier's programs](#).

I understand I can immediately share my article within my institution and privately with collaborators, and share my accepted manuscript publicly in my institution's repository after 12 months. I have additional article sharing rights outlined [here](#).

Publishing in Cell Press/ Lancet (APC discount)

- Authors are informed that they would need to provide a PO (being implemented)



These are the available publishing options.

If the journal accepts your article, you can change your mind about these options.

Note: editors and reviewers can only see your selection after acceptance.

IGlug



Gold Open Access



Publish as an Open Access article

Make my published article available to everyone upon acceptance.

As a corresponding author affiliated with the **University of Avignon**, upon validation, **the agreement between the French institutions and Elsevier will cover the APC with a valid purchase order number after acceptance.**

I will need to enter the valid PO number as part of the post acceptance journey. For guidance on how to collect PO number from my institution, I can refer to this [link](#).

To pay on acceptance



Only applicable if article accepted

Price
EUR 4,880.00



Institutional Agreement Discount
- 488.00

To pay (on validation)

(Excluding taxes)
EUR 4,392.00



Publishing options after acceptance

Review final and final distribution publication using a Microsoft Word document



Corresponding author	[Redacted]
E-mail address	[Redacted]
Journal	International Journal of Pharmaceutics
Article number	121624
Our reference	IJP_121624
PII	S0378-5173(22)00179-X

Welcome [Redacted]

To help us finalize the publication of your article please complete the publishing form(s) below.

Note: you will receive a confirmation e-mail after completing each form.

 Information you may need to provide to complete the forms



Rights and Access

[Complete the rights and access form >](#)

Help and Support

[How you can share your article](#)



[Author rights information](#)

[A guide to publishing Open Access](#)

Corresponding author receives an email post acceptance with a unique link to complete the author journey and choose publishing options

Author clicks on Complete the Rights and Access information form



Corresponding author selects his/her affiliation details which we use to identify the authors and match them to the Couperin Elsevier agreement

Please note that the author has already provided this information at submission; it is prepopulated

Corresponding author
E-mail address
Journal
Article number
Our reference
PII
DOI

Corresponding Author's Organization ⓘ

Please enter the corresponding author's organization. We use this information so we can offer tailored publishing options and a personalized article publishing charge for Gold open access when applicable.

Hint: start your search using your main organization name (e.g. University of Manchester) as this will return the most results from which to select the most appropriate option. If you're unable to find your specific department, then selecting your main organization is sufficient. For more tips on searching for an organization please visit our [Support Center](#).

- Organization name*
- Nantes University
 - Nantes University**
Nantes, FR
 - Nantes Universite
Nantes, FR
 - Nantes Université
Nantes, FR
 - University of Nantes
Nantes, FR
 - Centre Hospitalier Universitaire de Nantes
Nantes, FR
 - University Hospital Centre Nantes
Nantes, FR
 - Nantes University University Library

Save and Continue >

All content on t
technologies.
We use cookies

All rights are reserved, including those for text and data mining, AI training, and similar



▼

Were there any co-authors for this article?

Yes

No

Add Co-author Details ⓘ

Please provide details for all co-authors. We use this information so we can offer tailored publishing options and a personalized article publishing charge for Gold open access when applicable.

Hint: start the organization search using the main organization name (e.g. University of Manchester) as this will return the most results from which to select the most appropriate option. If you're unable to find the specific department, then selecting the main organization is sufficient. For more tips on searching for an organization please visit our [Support Center](#).

First name or initial*	Last name*	
<input type="text" value="John"/>	<input type="text" value="Head"/>	

Organization name*

Or use recently selected organization

[+ Add another co-author](#)

Corresponding author also adds the co-author affiliation details



Author can add the Funder details. Funder can be the affiliated institution or a different one. In this case it is Milliman



Did the research in this article receive funding?

Yes
 No

Funder Details ⓘ

Determine the best publishing options for your article. Please include the details about any funding received outside of your primary affiliations. If providing details for two or more organizations, please list the organization(s) that provided the most funding first.

For tips on searching for an organization please visit our [Support Center](#)

Organization name*

Milliman Inc



Grant/Contract numbers*

GT123



+ Add grant/contract number

+ Add another organization

Previous

Save and Continue >

- Based on the affiliation details, the author sees the **Publishing Options. Gold OA option is followed by Subscription option, and we inform the author that agreement covers the APC**
- **If the librarian/admin at the institution rejects the author request in the Elsevier Platform, we also make it clear that the authors will receive a full price invoice**
- **Author selects Gold OA**

Gold Open Access

Publish as an Open Access article

Make my published article available to everyone.

As an author affiliated with the **Nantes University**, upon validation, [the agreement between the French higher education and research institutions consortium \(Couperin\) and Elsevier](#) [↗](#) may cover the Article Publishing Charge.

Please check with your institution regarding the open access policy.

I and others can share and reuse my article in the ways described by the user license I select.

Article Publishing Charge (APC)

Price
EUR 3,120.00

 Institutional Agreement Discount
- 3,120.00

To pay (on validation)
0.00



If your institution cannot confirm your affiliation, you will receive a full price invoice for EUR 3,120.00 (ex. VAT). Within 2 weeks of receiving an invoice, you may contact [Researcher Support](#) to publish free of charge under the Subscription model.

[Couperin and Elsevier Agreement](#)

Subscription

Publish as a subscription article

I will publish my article subscription, making my final published article immediately available to journal subscribers, and to other groups as part of [Elsevier's programs](#) [↗](#).

I understand I can immediately share my article within my institution and privately with collaborators, and share my accepted manuscript publicly in my institution's repository after 5 March 2025. I have additional article sharing rights outlined [here](#) [↗](#).

Previous

Save and Continue >



Publishing in Cell Press/ Lancet (APC discount)

- Authors are informed that they would need to provide a PO (being implemented)



Based on information you have provided, your publishing option is shown below

Gold Open Access

Publish as an Open Access article

Make my published article available to everyone.

As an author affiliated with the **University of Lille**, upon validation, I will receive a 10% discount on the APC as part of the [agreement between the University of Lille and Elsevier](#).

I will need to enter the valid PO number in the PO number section below as it is mandatory. I can refer to this [link](#) to understand how I can receive a PO number for the institution. I will receive an invoice to pay the remainder of the APC from my institution.

I and others can share and reuse my article in the ways described by the user license I select.

Article Publishing Charge (APC)

Price
EUR 4,880.00

Institutional Agreement Discount
- 488.00

To pay (on validation)
(Excluding taxes)
EUR 4,392.00

If your institution cannot confirm your affiliation, you will receive a full price invoice for USD 5,460.00 (ex. VAT).

[University of Lille and Elsevier Agreement](#)

Add discount code >

Previous

Save and Continue >



Select your user license

Please select your license. If you need to comply with a mandated license and the mandated license is not listed below, please visit our [Support Hub](#) for additional help.

- CC BY 4.0**
[CC-BY license is the recommended choice]
A license to permit readers to share and adapt your article for any purpose, even commercially.
[Read more about CC BY 4.0](#) ▼

- CC BY-NC-ND 4.0**
A license to permit readers to share all or part of your article in any medium or format for non-commercial purposes. Permission from Elsevier is required for the distribution of derivative versions of the article or for commercial use.
[Read more about CC BY-NC-ND 4.0](#) ▼

- CC BY-NC 4.0**
A license for readers to share and adapt your article for non-commercial purposes. Permission from Elsevier is required for commercial use of the article.
[Read more about CC BY-NC 4.0](#) ▼

- **System presents the author with the CC license options**
- **CC BY is pre-selected**

Previous

Save and Continue >



Author selects the rights

How best do you describe your organization? [View all options](#)

Elsevier B.V.

Select Your Status

- I am the sole author of the manuscript
 - I am one author signing on behalf of all co-authors of the manuscript
- Please indicate which of the below applies to you:
- We are all US Government employees and the Article is public domain and therefore the 'License of publishing rights' clause does not apply
 - I am a US Government employee but some of my co-authors are not
 - I am not a US Government employee but some of my co-authors are
 - The work was performed by contractors of the US Government under contract number:
- Contract Number*
-
- All or some of the authors are UK, Canadian or Australian Government employees and Crown Copyright is asserted
 - Some of the authors are employees of the UK, Canadian or Australian Government but Crown Copyright is not asserted
 - None of the above
- I am signing as an authorized representative and on behalf of my employer

Signed on Behalf of Corresponding Author

Please complete this section if you are not the corresponding author as listed above. A copy of the agreement will be sent to you and the corresponding author.

I am signing on behalf of the corresponding author

Name, job title and company (if employer representative)*

E-mail address*

Previous

Save and Continue >

1

Corresponding
Author

2

Co-Author

3

Research
Funders

4

Publishing
Options

5

Licenses

6

Rights

7

Publishing
Agreement

8

Payment
Details

9

Review Order

10

Confirmation

Elsevier B.V.

Your Status

- I am one author signing on behalf of all co-authors of the manuscript

License of Publishing Rights

I hereby grant to Elsevier B.V. an irrevocable non-exclusive license to publish, distribute and otherwise use all or any part of the manuscript identified above and any tables, illustrations or other material submitted for publication as part of the manuscript (the "Article") in all forms and media (whether now known or later developed) in all languages, throughout the world, for the full term of copyright, and the right to license others to do the same, effective when the Article is accepted for publication.

I acknowledge the importance of the integrity, authenticity and permanence of the scholarly record and agree that the version of the Article that appears or will appear in the journal and embodies all value-adding publisher activities (including peer review co-ordination, copy-editing, formatting, (if relevant) pagination, and online enrichment) shall be the definitive final record of published research ("the Published Journal Article").

I further acknowledge and agree that nothing in this Agreement shall be deemed to permit redundant/duplicate publication of the Article in violation of publishing ethics principles, as further described below.

Supplemental Materials

"Supplemental Materials" shall mean materials published as a supplemental part of the Article, including but not limited to graphical, illustrative, video and audio material.

**System presents author
with the Journal License
Publishing Agreement**

**The non-exclusive license
agreement for the CC BY
license**

Author agrees to the Journal License Publishing Agreement

journal home page. For further information on sanctions, see <https://www.elsevier.com/about/our-business/policies/trade-sanctions> ↗

Author representations

- The Article I have submitted to the journal for review is original, has been written by the stated authors and has not been previously published.
- The Article was not submitted for review to another journal while under review by this journal and will not be submitted to any other journal.
- The Article and the Supplemental Materials do not infringe any copyright, violate any other intellectual property, privacy or other rights of any person or entity, or contain any libellous or other unlawful matter.
- I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in the Article or the Supplemental Materials.
- Except as expressly set out in this License Agreement, the Article is not subject to any prior rights or licenses which conflict with the terms of this License Agreement.
- If I and/or any of my co-authors reside in Russia, Belarus, Iran, Cuba, or Syria, the Article has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government or institution.
- If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by applicable law and complied with the publisher's policies relating to the use of such images or personal information. See <https://www.elsevier.com/about/our-business/policies/patient-consent> ↗ for further information.
- Any software contained in the Supplemental Materials is free from viruses, contaminants or worms.
- If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms of this License Agreement and that I am signing on their behalf as their agent, and I am authorized to do so.

Governing Law and Jurisdiction

This License Agreement will be governed by and construed in accordance with the laws of the country or state of Elsevier B.V. ("the Governing State"), without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the courts of the Governing State.

For information on the publisher's copyright and access policies, please see <http://www.elsevier.com/copyright> ↗.

I have read and agree to the terms of the License Agreement.

9 February 2024

T-copyright license-v5/2017

Previous

Accept Agreement >

Rights and Access

**Once the author clicks on Finish:**

- Corresponding author and coauthors receive a copy of summary via email
- Article becomes OA on ScienceDirect within 24 hours
- Librarian/admin at the institution will receive a notification for validation within 48 hours who then has 3 weeks to validate the request
- If the Librarian/admin approves the request, the author will receive the full APC coverage
- If the Librarian/admin rejects the request, the author will have a choice to pay or publish subscription free of charge



Review Order

Research Funders	Milliman Inc Grant numbers: GT123
Publishing Option	Gold Open Access
User License	CC BY 4.0
Publishing Agreement	<ul style="list-style-type: none">I am one author signing on behalf of all co-authors of the manuscript and I am duly authorized to do so by all co-authors of the manuscript <p>I may share my final published article widely in accordance with the user License that I have selected. Further details on Elsevier Sharing Policy here.</p>

6 June 2024

Previous

Total payment due

Price (excluding taxes)
EUR 3,120.00

Institutional Agreement Discount
 - 3,120.00

To pay (on validation)
 **0.00**

If your institution cannot confirm your affiliation, you will receive a full price invoice for EUR 3,120.00 (ex. VAT). Within 2 weeks of receiving an invoice, you may contact [Researcher Support](#) to publish free of charge under the Subscription model.

[Couperin and Elsevier Agreement](#)

Finish >

Support for authors and librarians/administrators

- For Authors– oasupport@elsevier.com
- For Librarians/Administrators, related to activating or modifying EOAP–
agreementactivation@elsevier.com
- APC Couperin Team:apc@couperin.org

Links

[Hub client Couperin \(elsevier.com\)](#)

[Elsevier < Couperin](#)

[Find a journal | Journal Finder
\(elsevier.com\)](#)